The ability of IGFBP7 expression to identify breast cancers more likely to respond to ganitumab/metformin plus chemotherapy than to chemotherapy alone was most apparent in TNBC, where 66.7% of IGFBP7 Q1 tumors and no IGFBP7 Q4 tumors achieved pCR (Table 3). Here, IGFBP7 is linked to breast cancer.